# This Page Is Inserted by IFW Operations and is not a part of the Official Record

#### **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

### IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this REQUEST and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450; Alexandria, VA 22313-

Applicant:

Brooks, et al.

Serial No.:

09/081,522

Filed:

May 19, 1998

Title: INHIBITION OF ANGIOGENESIS

IN DISEASE STATES WITH AN ANTI-ανβ3 MONOCLONAL

ANTIBODY (AS AMENDED)

Group Art Unit: 1644

Examiner: P. Gambel

Confirmation No. 1607

Our Ref.: TSRI 419.0 Con 1

#### FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56 and §1.97

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Applicants hereby direct the Examiner's attention to the references listed on the attached revised form PTO-1449 entitled "List of References Cited by Applicant." A legible copy of the fifteen attached references are being submitted herewith.

Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Since this Supplemental Information Disclosure Statement is being filed before the mailing date of the first Office Action after the filing of a Request for Continued

1485640.1

Examination under §1.114, the fee required to be filed with the accompanying Supplemental Information Disclosure Statement has been estimated to be <u>\$0.00</u>. However, should the Patent Office determine otherwise, please charge the required fee to Deposit Account No. 19-0962. A copy of this sheet is enclosed for accounting purposes.

December 29, 2003

Date
THE SCRIPPS RESEARCH INSTITUTE
Office of Patent Counsel
10550 North Torrey Pines Road
Mail Drop TPC-8
La Jolla, California 92037
(858) 784-2937

Respectfully submitted,

Thomas Fitting, Reg. No. 34,163

U.S. PATENT DOCUMENTS  **EXAMINER NAME   DOCUMENT NUMBER   DATE   NAME   CLASS   SUBCLASS   FAPROPH   NITTAL   A01   5,578,704   11/26/96   Kim   A02   5,652,109   7/29/97   Kim   A03   5,652,110   7/29/97   Kim   A03   5,652,110   7/29/97   Kim   A04   5,677,181   10/14/97   Parish   A05   5,674,181   10/14/97   Parish   A06   5,677,181   10/14/97   Parish   A07   5,677,181   10/14/97   Parish   A08   5,874,081   02/23/99   Parish   A08   5,874,081   02/23/99   Parish   A08   5,874,081   02/23/99   Parish   A09   5,677,181   10/14/97   Parish   A09   A09	LIST OF REFERENCES CITED BY APPLICANT					TSRI 419.0 C1		APPLICATION NO 09/081,522		
U.S. PATENT DOCUMENTS  DOCUMENT NUMBER A01 5,578,704 11/26/96 Kim A02 5,652,109 7/29/97 Kim A03 5,652,110 7/29/97 Kim A03 5,652,110 7/29/97 Kim A04 5,677,181 10/14/97 Parish B01 VO 94/10331 02/23/99 Parish  FOREIGN PATENT DOCUMENTS  FOREIGN PATENT DOCUMENTS  FOREIGN PATENT DOCUMENTS  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)  C01 Adams et al., "Increased Affinity Leads to Improved Selective Tumor Delivery of Single-Chain Fv Antibodies," Cancer Research 58: 485-490 (1998).  C02 Carmeliet, "Integrin indecision," Nature Medicine 8: 14-16 (2002).  C03 Cheresh, "Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor," Proc. Natl. Acad. Sci. USA 84: 6471-6475 (1987).  C04 Cheresh et al., "Integrin-mediated death: An explanation of the integrin-knockout phenotype?" Nature Medicine 8: 193-194 (2002).  C05 Posey et al., "Pilot Trial of Vitaxin, A Humanized Anti-Vitronectin Receptor (anti α.β.) Antibody in Patients with Metastatic Cancer," Cancer Biotherapy & Radiopharmaceuticals 16: 125-132 (2001).  C06 Rader et al., "Integrin-mediated death: An explanation of the integrin-knockout phenotype?" Nature Medicine Proc. Natl. Acad. Sci. USA 84: 6471-6475 (1987).  C07 Reynolds et al., "Balanced pathological angiogenesis in mice lacking β, integrin or β, and β, integrins," Nature Medicine 8: 27-34 (2002).  C08 Schier et al., "Balanced pathological angiogenesis in mice lacking β, integrin or β, and β, integrins," Nature Medicine 8: 27-34 (2002).  C09 Schier et al., "Balanced pathological angiogenesis in mice lacking β, integrin or β, and β, integrins," Nature Medicine 8: 27-34 (2002).  C09 Schier et al., "Balanced pathological angiogenesis in mice lacking β, integrin or β, and β, integrins," Nature Medicine 8: 27-34 (2002).  C09 Schier et al., "Balanced pathological angiogenesis in mice lacking β, integrin or β,		, IOI.	(Use several sheets if	r APPLIC	ANI	1				_
U.S. PATENT DOCUMENTS    EXAMINER   DOCUMENT NUMBER   DATE   NAME   CLASS   SUBCLASS   FILINOD						_		1		
DOCUMENT NUMBER  A01 5,578,704 11/26/96 Kim  A02 5,652,110 7/29/97 Kim  A03 5,652,110 7/29/97 Kim  A03 5,652,110 7/29/97 Kim  A04 5,677,181 10/14/97 Parish  A65 5,874,081 02/23/99 Parish  FOREIGN PATENT DOCUMENTS  FOREIGN PATENT DOCUMENTS  FOREIGN PATENT DOCUMENTS  DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLAT YES  B01 WO 94/10331 5/11/94  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)  C01 Adams et al., "Increased Affinity Leads to Improved Selective Tumor Delivery of Single-Chain Fv Antibodies," Cancer Research 58: 485-490 (1998).  C02 Carmeliet, "Integrin indecision," Nature Medicine 8: 14-16 (2002).  C03 Cheresh, "Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor," Proc. Natl. Acad. Sci USA 84: 6471-6475 (1987).  C04 Cheresh et al., "Integrin-mediated death: An explanation of the integrin-knoch phenotype?" Nature Medicine 8: 193-194 (2002).  C05 Posey et al., "Pilot Trial of Vitaxin, A Humanized Anti-Vitronectin Receptor (anti α.β.) Antibody in Patients with Metastatic Cancer," Cancer Biotherapy & Radiopharmaceuticals 16: 125-132 (2001).  C06 Rader et al., "Bhanced pathological angiogenesis in mice lacking β, integrin or β, and β, integrins," Nature Medicine 8: 27-34 (2002).  C07 Reynolds et al., "Enhanced pathological angiogenesis in mice lacking β, integrin or β, and β, integrins," Nature Medicine 8: 27-34 (2002).  C08 Schier et al., "Solation of Filemolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site," J. Mol. Biol. 263: 551-567				U.S. P	ATENT DOCUM			1044		
A02 5,652,109 7/29/97 Kim  A03 5,652,110 7/29/97 Kim  A03 5,652,110 7/29/97 Kim  A03 5,652,110 7/29/97 Kim  A03 5,657,181 10/14/97 Parish  FOREIGN PATENT DOCUMENTS  FOREIGN PATENT DOCUMENTS  FOREIGN PATENT DOCUMENTS  B01 WO 94/10331 5/11/94 YES  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)  C01 Adams et al., "Increased Affinity Leads to Improved Selective Tumor Delivery of Single-Chain Fv Antibodies," Cancer Research 58: 485-490 (1998).  C02 Carneliet, "Integrin indecision," Nature Medicine 8: 14-16 (2002).  C03 Cheresh, "Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor," Proc. Natl. Acad. Sci USA 84: 6471-6475 (1987).  C04 Cheresh et al., "Integrin-mediated death: An explanation of the integrin-knockout phenotype?" Nature Medicine 8: 19-194 (2002).  C05 Posey et al., "Pilot Trial of Vitaxin, A Humanized Anti-Vitronectin Receptor (anti c.,β.) Antibody in Patients with Metastatic Cancer," Cancer Biotherapy & Radiopharmaceuticals 16: 125-132 (2001).  C06 Rader et al., "Enhanced pathological angiogenesis in mice lacking β, integrin or β, and β, integrins," Nature Medicine 8: 27-34 (2002).  C07 Reynolds et al., "Enhanced pathological angiogenesis in mice lacking β, integrin or β, and β, integrins," Nature Medicine 8: 27-34 (2002).  C08 Schier et al., "Isolation of Fligh-affinity Monomeric Human Anti-c-erbB-2 Single chain Fv Using affinity-driven Selection," J. Mol. Biol. 255: 28-43 (1996).  C09 Schier et al., "Isolation of Flicomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site," J. Mol. Biol. 263: 551-567			DOCUMENT NUMBER			ME	CLASS	SUBCLASS	FILING	DAT.
A03 5,652,110 7/29/97 Kim  5,677,181 10/14/97 Parish  6,874,081 02/23/99 Parish  FOREIGN PATENT DOCUMENTS  FOREIGN PATENT DOCUMENTS  DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLAT  B01 WO 94/10331 5/11/94 YES  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)  C01 Adams et al., "Increased Affinity Leads to Improved Selective Tumor Delivery of Single-Chain Fv Antibodies," Cancer Research 58; 485-490 (1998).  C02 Carmeliet, "Integrin indecision," Nature Medicine 8: 14-16 (2002).  C03 Cheresh, "Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor," Proc. Natl. Acad. Sci USA 84; 6471-6475 (1987).  C04 Cheresh at i., "Integrin-mediated death: An explanation of the integrin-knockout phenotype?" Nature Medicine 8: 193-194 (2002).  C05 Posey et al., "Pilot Trial of Vitaxin, A Humanized Anti-Vitronectin Receptor (anti α.β.) Antibody in Patients with Metastatic Cancer," Cancer Biotherapy & Radiopharaceuticals 16: 125-132 (2001).  C06 Rader et al., "Phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries," Proc. Natl. Acad. Sci. USA 95: 8910-8915 (1998).  C07 Reynolds et al., "Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β3 integrins," Nature Medicine 8: 27-34 (2002).  C08 Schier et al., "Isolation of High-affinity Monomeric Human Anti-c-erbB-2 Single chain Fv Using affinity-driven Selection," J. Mol. Biol. 255: 28-43 (1996).  C09 Schier et al., "Isolation of Piccomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site," J. Mol. Biol. 263: 551-567 (1996).						-		1 2 2 2 2 1 1 2 2	II AITKO	JFK1A
FOREIGN PATENT DOCUMENTS  FOREIGN PATENT DOCUMENTS  DOCUMENT NUMBER  DATE  COUNTRY  CLASS SUBCLASS TRANSLAY  B01 WO 94/10331  S/11/94  COTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)  CO1 Adams et al., "Increased Affinity Leads to Improved Selective Tumor Delivery of Single-Chain Fv Antibodies," Cancer Research 58: 485-490 (1998).  CO2 Carmeliet, "Integrin indecision," Nature Medicine 8: 14-16 (2002).  CO3 Cheresh, "Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor," Proc. Natl. Acad. Sci USA 84: 6471-6475 (1987).  CO4 Cheresh et al., "Integrin-mediated death: An explanation of the integrin-knockour phenotype?" Nature Medicine 8: 193-194 (2002).  CO5 Posey et al., "Pilot Trial of Vitaxin, A Humanized Anti-Vitronectin Receptor (anti α,β <sub>3</sub> ) Antibody in Patients with Metastatic Cancer," Cancer Biotherapy & Radiopharmaceuticals 16: 125-132 (2001).  CO6 Rader et al., "Enhanced pathological angiogenesis in mice lacking β <sub>3</sub> integrin or β <sub>3</sub> and β <sub>3</sub> integrins," Nature Medicine 8: 27-34 (2002).  CO7 Reynolds et al., "Enhanced pathological angiogenesis in mice lacking β <sub>3</sub> integrin or β <sub>3</sub> and β <sub>3</sub> integrins," Nature Medicine 8: 27-34 (2002).  CO8 Schier et al., "Isolation of High-affinity Monomeric Human Anti-c-erbB-2 Single chain Fv Using affinity-driven Selection," J. Mol. Biol. 255: 28-43 (1996).  Sohier et al., "Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site," J. Mol. Biol. 263: 551-567					Kim			1		
FOREIGN PATENT DOCUMENTS    DOCUMENT NUMBER   DATE   COUNTRY   CLASS   SUBCLASS   TRANSLAN	15	_			Kim					
FOREIGN PATENT DOCUMENTS    DOCUMENT NUMBER   DATE   COUNTRY   CLASS   SUBCLASS   TRANSLAT	1017	<del>Q</del> ``	<u></u>	10/14/97	Parish		<del> </del>			
DOCUMENT NUMBER   DATE   COUNTRY   CLASS   SUBCLASS   TRANSLATE	· .	APC	5,874,081	02/23/99	Parish		<del> </del>			
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)  C01 Adams et al., "Increased Affinity Leads to Improved Selective Tumor Delivery of Single-Chain Fv Antibodies," Cancer Research 58: 485-490 (1998).  C02 Carmeliet, "Integrin indecision," Nature Medicine 8: 14-16 (2002).  C03 Cheresh, "Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor," Proc. Natl. Acad. Sci USA 84: 6471-6475 (1987).  8:193-194 (2002).  C05 Posey et al., "Pilot Trial of Vitaxin, A Humanized Anti-Vitronectin Receptor (anti α,β) Antibody in Patients with Metastatic Cancer," Cancer Biotherapy & Radiopharmaceuticals 16: 125-132 (2001).  C06 Rader et al., "Phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries," Proc. Natl. Acad. Sci. USA 95: 8910-8915 (1998).  C07 Reynolds et al., "Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β3 integrins," Nature Medicine 8: 27-34 (2002).  C08 Schier et al., "Isolation of High-affinity Monomeric Human Anti-c-erbB-2 Single chain Fv Using affinity-driven Selection," J. Mol. Biol. 255: 28-43 (1996).  C09 Schier et al., "Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site," J. Mol. Biol. 263: 551-567	EDMORN	MILETE	DOCUMENT NUMBER	1	<del></del>		CLASS			
<ul> <li>OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)</li> <li>C01 Adams et al., "Increased Affinity Leads to Improved Selective Tumor Delivery of Single-Chain Fv Antibodies," Cancer Research 58: 485-490 (1998).</li> <li>C02 Carmeliet, "Integrin indecision," Nature Medicine 8: 14-16 (2002).</li> <li>C03 Cheresh, "Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor," Proc. Natl. Acad. Sci USA 84: 6471-6475 (1987).</li> <li>C04 Cheresh et al., "Integrin-mediated death: An explanation of the integrin-knockout phenotype?" Nature Medicine 8: 193-194 (2002).</li> <li>C05 Posey et al., "Pilot Trial of Vitaxin, A Humanized Anti-Vitronectin Receptor (anti α,β3) Antibody in Patients with Metastatic Cancer," Cancer Biotherapy &amp; Radiopharmaceuticals 16: 125-132 (2001).</li> <li>C06 Rader et al., "Phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries," Proc. Natl. Acad. Sci. USA 95: 8910-8915 (1998).</li> <li>C07 Reynolds et al., "Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β3 integrins," Nature Medicine 8: 27-34 (2002).</li> <li>C08 Schier et al., "Isolation of High-affinity Monomeric Human Anti-c-erbB-2 Single chain Fv Using affinity-driven Selection," J. Mol. Biol. 255: 28-43 (1996).</li> <li>C09 Schier et al., "Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site," J. Mol. Biol. 263: 551-567</li> </ul>	1		WO 04/10221	6/11/04			CLASS	SUBCLASS	TRANSLATIO	
<ul> <li>C01 Adams et al., "Increased Affinity Leads to Improved Selective Tumor Delivery of Single-Chain Fv Antibodies," Cancer Research 58: 485-490 (1998).</li> <li>C02 Carmeliet, "Integrin indecision," Nature Medicine 8: 14-16 (2002).</li> <li>C03 Cheresh, "Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor," Proc. Natl. Acad. Sci USA 84: 6471-6475 (1987).</li> <li>C04 Cheresh et al., "Integrin-mediated death: An explanation of the integrin-knockout phenotype?" Nature Medicine 8: 193-194 (2002).</li> <li>C05 Posey et al., "Pilot Trial of Vitaxin, A Humanized Anti-Vitronectin Receptor (anti α,β3) Antibody in Patients with Metastatic Cancer," Cancer Biotherapy &amp; Radiopharmaceuticals 16: 125-132 (2001).</li> <li>C06 Rader et al., "Phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries," Proc. Natl. Acad. Sci. USA 95: 8910-8915 (1998).</li> <li>C07 Reynolds et al., "Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins," Nature Medicine 8: 27-34 (2002).</li> <li>C08 Schier et al., "Isolation of High-affinity Monomeric Human Anti-c-erbB-2 Single chain Fv Using affinity-driven Selection," J. Mol. Biol. 255: 28-43 (1996).</li> <li>C09 Schier et al., "Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site," J. Mol. Biol. 263: 551-567</li> </ul>		BUI	110 74/10331	3/11/94					123	N
<ul> <li>Co2 Carmeliet, "Integrin indecision," Nature Medicine 8: 14-16 (2002).</li> <li>Cheresh, "Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor," Proc. Natl. Acad. Sci USA 84: 6471-6475 (1987).</li> <li>Co3 Cheresh et al., "Integrin-mediated death: An explanation of the integrin-knockout phenotype?" Nature Medicine 8:193-194 (2002).</li> <li>Co5 Posey et al., "Pilot Trial of Vitaxin, A Humanized Anti-Vitronectin Receptor (anti α,β3) Antibody in Patients with Metastatic Cancer," Cancer Biotherapy &amp; Radiopharmaceuticals 16: 125-132 (2001).</li> <li>Co6 Rader et al., "Phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries," Proc. Natl. Acad. Sci. USA 95: 8910-8915 (1998).</li> <li>Co7 Reynolds et al., "Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins," Nature Medicine 8: 27-34 (2002).</li> <li>Co8 Schier et al., "Isolation of High-affinity Monomeric Human Anti-c-erbB-2 Single chain Fv Using affinity-driven Selection," J. Mol. Biol. 255: 28-43 (1996).</li> <li>Co9 Schier et al., "Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site," J. Mol. Biol. 263: 551-567</li> </ul>		C01	Adams et al., "Increased Cancer Research 58: 485	Affinity Leads	s to Improved Selectiv	e Tumor Delivery	Pages, E	<i>tc.)</i> hain Fv Ant	bodies,"	
C03 Cheresh, "Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor," Proc. Natl. Acad. Sci USA 84: 6471-6475 (1987).  C04 Cheresh et al., "Integrin-mediated death: An explanation of the integrin-knockout phenotype?" Nature Medicine 8:193-194 (2002).  C05 Posey et al., "Pilot Trial of Vitaxin, A Humanized Anti-Vitronectin Receptor (anti α,β₃) Antibody in Patients with Metastatic Cancer," Cancer Biotherapy & Radiopharmaceuticals 16: 125-132 (2001).  C06 Rader et al., "Phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries," Proc. Natl. Acad. Sci. USA 95: 8910-8915 (1998).  C07 Reynolds et al., "Enhanced pathological angiogenesis in mice lacking β₃ integrin or β₃ and β₅ integrins," Nature Medicine 8: 27-34 (2002).  C08 Schier et al., "Isolation of High-affinity Monomeric Human Anti-c-erbB-2 Single chain Fv Using affinity-driven Selection," J. Mol. Biol. 255: 28-43 (1996).  C09 Schier et al., "Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site," J. Mol. Biol. 263: 551-567		C02	Carmeliet, "Integrin inde	cision," Nature	e Medicine 8: 14-16 (2	2002).		<del></del>		
<ul> <li>8:193-194 (2002).</li> <li>C05 Posey et al., "Pilot Trial of Vitaxin, A Humanized Anti-Vitronectin Receptor (anti α<sub>ν</sub>β<sub>3</sub>) Antibody in Patients with Metastatic Cancer," Cancer Biotherapy &amp; Radiopharmaceuticals 16: 125-132 (2001).</li> <li>C06 Rader et al., "Phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries," Proc. Natl. Acad. Sci. USA 95: 8910-8915 (1998).</li> <li>C07 Reynolds et al., "Enhanced pathological angiogenesis in mice lacking β<sub>3</sub> integrin or β<sub>3</sub> and β<sub>5</sub> integrins," Nature Medicine 8: 27-34 (2002).</li> <li>C08 Schier et al., "Isolation of High-affinity Monomeric Human Anti-c-erbB-2 Single chain Fv Using affinity-driven Sclection," J. Mol. Biol. 255: 28-43 (1996).</li> <li>C09 Schier et al., "Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site," J. Mol. Biol. 263: 551-567</li> </ul>		C03	Cheresh, "Human endoth attachment to fibringen	elial cells synt	thesize and express an	Arg-Gly-Asp-direc	ted adhesic	on receptor i	nvolved i	n
<ul> <li>C06 Rader et al., "Phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries," Proc. Natl. Acad. Sci. USA 95: 8910-8915 (1998).</li> <li>C07 Reynolds et al., "Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins," Nature Medicine 8: 27-34 (2002).</li> <li>C08 Schier et al., "Isolation of High-affinity Monomeric Human Anti-c-erbB-2 Single chain Fv Using affinity-driven Selection," J. Mol. Biol. 255: 28-43 (1996).</li> <li>C09 Schier et al., "Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site," J. Mol. Biol. 263: 551-567</li> </ul>			8:193-194 (2002).	double	All explanation of fi	ie integrin-knockou	t phenotyp	e?" Nature N	ledicine	
<ul> <li>C06 Rader et al., "Phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries," Proc. Natl. Acad. Sci. USA 95: 8910-8915 (1998).</li> <li>C07 Reynolds et al., "Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins," Nature Medicine 8: 27-34 (2002).</li> <li>C08 Schier et al., "Isolation of High-affinity Monomeric Human Anti-c-erbB-2 Single chain Fv Using affinity-driven Selection," J. Mol. Biol. 255: 28-43 (1996).</li> <li>C09 Schier et al., "Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site," J. Mol. Biol. 263: 551-567</li> </ul>		C05	Posey et al., "Pilot Trial of Metastatic Cancer." Cons	of Vitaxin, A H	Iumanized Anti-Vitror	nectin Receptor (an	ti α <sub>ν</sub> β <sub>3</sub> ) An	tibody in Pa	ients with	h
C07 Reynolds et al., "Enhanced pathological angiogenesis in mice lacking β <sub>3</sub> integrin or β <sub>3</sub> and β <sub>5</sub> integrins," Nature  Medicine 8: 27-34 (2002).  C08 Schier et al., "Isolation of High-affinity Monomeric Human Anti-c-erbB-2 Single chain Fv Using affinity-driven Selection," J. Mol. Biol. 255: 28-43 (1996).  C09 Schier et al., "Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site," J. Mol. Biol. 263: 551-567  (AMINER	· · · · · · · · · · · · · · · · · · ·		Rader et al., "Phage disple Proc. Natl. Acad. Sci. US	ay approach fo	or rapid antibody huma	anization: Designed	combinate	orial V gene	libraries,'	,
Cop Schier et al., "Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site," J. Mol. Biol. 263: 551-567  (AMINER	)	C07 Reynolds et al., "Enhanced pathological angiogenesis in mice lacking β <sub>3</sub> integrin or β <sub>3</sub> and β <sub>5</sub> integrins," Nature								
Complementarity Determining Regions in the Center of the Antibody Binding Site," J. Mol. Biol. 263: 551-567  (AMINER		C08	Schier et al., "Isolation of Selection," J. Mol. Biol. 2	High-affinity 55: 28-43 (19	Monomeric Human A 96).	nti-c-erbB-2 Single	chain Fv I	Jsing affinit	y-driven	
KAMINER DATE CONSIDERED		C09	Schier et al., "Isolation of	Picomolar A 6	Similar A -4: - 1 TO C C	ingle-chain Fv by N ntibody Binding Si	Molecular E te," <u>J. Mol.</u>	volution of Biol. 263: 5	the 51-567	
	XAMINER				DATE CO	NSIDERED				